Maintenance Rituxan® Is Safe for Follicular Lymphoma(7/8/2008) Researchers affiliated with the International IIIb MAXIMA trial have reported that continued treatment for up to two years with Rituxan® (rituximab) is a safe therapeutic approach for the treatment of follicular lymphoma. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago June 2-May 30.
Epoetin-beta in Cancer Patients Not Associated with Increased Relapses or Mortality(7/8/2008) Researchers from Switzerland have reported that epoetin-beta does not increase the risk of relapse, mortality, or thromboembolic mortality in patients with cancer. The details of this meta-analysis study were published in an early online publication in the British Journal of Cancer.
Highlights from the 2007 San Antonio Breast Cancer Symposium (SABCS) - CME This independent conference coverage provides expert updates in the management of breast cancer from Dr. Lee Schwartzberg, Dr. Lori Goldstein, Dr. Georgiana Ellis, and more. Continuing Medical Education credits will be available soon. More
Click here for an expert interview with Dr. Lee Schwartzberg of the West Clinic on Highlights and Clinical Impact of the data from the 2007 SABCS on metastatic breast cancer.
Highlights from the 49th Annual Meeting of the American Society of Hematology (ASH) - CME This independent conference coverage provides expert updates in the management of Immune Thrombocytopenic Purpura, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, and other hematologic malignancies, authored by Hagop Kantarjian, MD; Mikkael Sekeres, MD; and Charles Abrams, MD. Continuing Medical Education credits will be available soon. More
Highlights from the 12th World Conference on Lung Cancer - CME This independent conference coverage provides expert updates in the management of non-small cell lung cancer, small cell lung cancer and malignant pleural mesothelioma, authored by Chandra Belani, MD, Penn State Cancer Center, Hershey, PA;David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; andDavid Jackman, MD, Dana-Farber Cancer Institute, Boston, MD. More
New Agents for the Treatment of Lymphoma: A Review of the LiteratureCME Interactive Literature Review Fredrick B. Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
With Comments by John P. Leonard, MD, Associate Professor of Medicine, Weill Medical College of Cornell University; Clinical Director, New York-Cornell Center for Lymphoma and Myeloma in New York City Release date: March 30, 2007.
Case Study in Refractory Anemia-CME Interactive Case Study Ravi Vij, MD, Washington University in St. Louis School of Medicine. Release date: February 1, 2007.
Clinical Hold Lifted for Entereg®(7/7/2008) The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on Adolor Corporation’s constipation drug Entereg® (alvimopan). Entereg is being developed with GlaxoSmithKline PLC for the treatment of chronically constipated patients who are taking opioid drugs for pain.
Medicare and Medicaid Guidelines for Epoetin and Darbepoetin for Non-Renal Indications(8/3/2007) The Centers for Medicare and Medicaid Services (CMS) has published new guidelines for the use of erythropoiesis stimulating agents (ESAs) for non-renal indications.These guidelines are important since they guide reimbursement for epoetin (Procrit®, Epogen®) and darbepoetin (Aranesp®) in cancer patients.
Patient Home
